HealthEquity HQY
$
Relative Strength Index (RSI)
- The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. It is typically used to identify overbought or oversold conditions in financial markets.
- The RSI is calculated using the following formula:
RSI = 100 - (100 / (1 + RS))
Where RS is the ratio of the average gains to the average losses over a specified period.
- The default time period used is 14 days.
- RSI values range between 0 and 100.
RSI values above 70 are considered overbought (indicating a potentially opportune time to sell)
RSI values below 30 are considered oversold (indicating a potentially opportune time to buy)
RSI is not a perfect indicator and should be used in conjunction with other technical analysis tools, this is for informational purposes only and is not a substitute for professional financial advice.
Key Insights
HealthEquity (HQY) Core Market Data and Business Metrics
Latest Closing Price
$88.74Price-Earnings Ratio
81.41Total Outstanding Shares
86.50 Million SharesDividend
No dividendSIC Description
Services-business Services, NecPrimary Exchange
NASDAQHeadquarters
15 West Scenic Pointe Drive, Draper, UT, 84020
Historical Stock Splits
| Execution Date | Split Amount |
|---|---|
| No Historical Stock Splits | |
Short Interest
Track Short Interest Levels to Gauge Bearish Market Sentiment and Short Squeeze Potential
| Avg Daily Volume | Days to Cover | Settlement Date | Short Interest |
|---|---|---|---|
| 852,096 Shares | 4.85 | 3/14/2025 | 4,131,354 Shares |
| 625,092 Shares | 6.89 | 2/28/2025 | 4,307,148 Shares |
| 792,004 Shares | 5.5 | 2/14/2025 | 4,359,200 Shares |
| 662,280 Shares | 6.64 | 1/31/2025 | 4,396,955 Shares |
| 801,415 Shares | 5.64 | 1/15/2025 | 4,523,220 Shares |
| 816,478 Shares | 5.15 | 12/31/2024 | 4,201,972 Shares |
Cash Flow Statement
February 1, 2024 to January 31, 2025
| Metric | Value |
|---|---|
| Net Cash Flow From Financing Activities, Continuing | $57.57 Million |
| Net Cash Flow From Investing Activities, Continuing | $-505.45 Million |
| Net Cash Flow | $-108.03 Million |
| Net Cash Flow From Financing Activities | $57.57 Million |
| Net Cash Flow, Continuing | $-108.03 Million |
| Net Cash Flow From Operating Activities, Continuing | $339.86 Million |
Income Statement
February 1, 2024 to January 31, 2025
| Metric | Value |
|---|---|
| Income Tax Expense/Benefit | $19.33 Million |
| Research and Development | $239.51 Million |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $0 |
| Net Income/Loss Attributable To Parent | $96.70 Million |
| Income Tax Expense/Benefit, Deferred | $-12.83 Million |
| Gross Profit | $777.26 Million |
Comprehensive Income
February 1, 2024 to January 31, 2025
| Metric | Value |
|---|---|
| Comprehensive Income/Loss Attributable To Noncontrolling Interest | $0 |
| Comprehensive Income/Loss Attributable To Parent | $96.70 Million |
| Comprehensive Income/Loss | $96.70 Million |
| Other Comprehensive Income/Loss | $96.70 Million |
Balance Sheet
February 1, 2024 to January 31, 2025
| Metric | Value |
|---|---|
| Noncurrent Liabilities | $1.18 Billion |
| Equity Attributable To Noncontrolling Interest | $0 |
| Current Liabilities | $156.32 Million |
| Other Non-current Assets | $1.76 Billion |
| Current Assets | $477.75 Million |
| Wages | $69.33 Million |
Historical Dividends
| Announcement Date | Payment Date | Record Date | Amount | Frequency |
|---|---|---|---|---|
| No historical dividends | ||||